REFERENCES

4. Elger M, Sakai T, Kriz W: Role of mesangial cell contraction in adaptation of the glomerular tuft to changes in extracellular volume. Pflugers Arch 415: 598–605, 1990

We AIM2 Inflame

Andreas Linkermann, Simon P. Parmentier, and Christian Hugo

Division of Nephrology, Department of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany


The AIM2 inflammasome senses DNA released by necrotic renal cells and translates a deadly signal into a proinflammatory trigger, thereby providing a prototype example of necroinflammation. Loss of cellular membrane integrity (necrosis) represents a genetically determined and highly regulated process during AKI. During recent years, a discussion on the role of regulated necrosis as a novel therapeutic target during transplantation has emerged, but interestingly not because interference with necrotic cell death might preserve renal cell survival. Prevention of necrosis rather prevents the immunogenicity of necrotic debris. When any cell loses its membrane integrity, two steps follow. First, this cell loses most of its function. In the case of a tubular cell, this may represent features of AKI. Second, intracellular debris (often referred to as damage-associated molecular patterns) becomes accessible to surveilling immune cells. In the case of kidney transplantation, such cells become strongly activated and primed (e.g., in the case of B cells). On immunosuppression during the transplant process, immediate immunogenic responses (rejections) are prevented. When immunosuppression is tapered months after transplantation, antibody-mediated rejections may then be triggered, e.g., after otherwise trivial viral infection. But how can necrotic debris conceptually be explained as the stimulating trigger of macrophages on a molecular level? An important set of well-controlled data regarding this long-standing obstacle now comes from the group of Daniel Muruve.

In this issue of the Journal of the American Society of Nephrology, Komada et al. detected expression levels of the inflammasomal protein absent in melanoma 2 (AIM2) in human kidney sections obtained from nondiseased margins of nephrectomies in which AIM2 is predominantly present in the glomeruli. However, in samples obtained from patients with diabetic nephropathy or hypertensive sclerosis, a strong upregulation of AIM2 expression in infiltrating CD45-positive leukocytes and in the tubular compartment was demonstrated. These human findings were in line with data generated from mice that...
underwent unilateral ureteral obstruction (UUO). In those samples of either whole kidney lysates or microdissected tubular and glomerular compartments, AIM2 mRNA and AIM2-knockout (AIM2-ko) controlled protein expressions were highly upregulated. The AIM2 data are particularly interesting because previous work on inflammasomes in the kidney demonstrated the involvement of another type of inflammasomes, the so-called NLRP3 inflammasome.6 Consequently, the authors compared NLRP3-deficient and AIM2-deficient mice alongside with NLRP3/AIM2 double knockout (NLRP3/AIM2-dko) mice in the UUO model. Interestingly, after 7 days of UUO treatment, similar levels of protection were reported for all three genetic models in tubular injury scores and KIM1 protein expression, suggesting a partially redundant role for the inflammasomes during renal damage. However, whereas KIM1 gene expression appeared to be remarkably reduced in the NLRP3/AIM2-dko mice compared with AIM2-ko mice or wild-type controls, these knockout mice did not show a significant difference in renal fibrosis, as measured by picrosirius red staining or collagen I expression. Such a faint interplay between NLRP3 and AIM2 has recently been described during Aspergillus infection.7

The authors next investigated the role of F4/80-positive macrophages. Whereas an almost six-fold higher F4/80-positive area was found in UUO-treated wild-type mice compared with untreated controls, this increase was reduced by approximately 50% in AIM2-ko and NLRP3/AIM2-dko mice, highlighting the role of macrophages in this model. Importantly, effector functions of inflammasomes are mediated though caspases (caspase-1, -4, -5, and -11) through proteolytic cleavage of pro–IL-1β and pro–IL-18. Clearly, the IL1β-to-pro–IL-1β and the IL-18-to-pro–IL-18 ratios were decreased in both AIM2-ko and NLRP3/AIM2-dko UUO kidney samples compared with wild-type UUO. This finding suggests the proinflammatory role of inflammasomal signaling to be significantly reduced in the knockout mice. In keeping with the hypothesis that the AIM2 inflammasome in macrophages contributes to renal damage during UUO, bone marrow transfer experiments in which wild-type bone marrow was transplanted to AIM2-deficient mice brought the dimension of injury back to wild-type control levels. This experiment excluded a significant pathophysiologic role of AIM2 in the tubular cell compartment.

Elegant FACS studies employing CD45/F4/80 double-positive gating of kidney-derived samples revealed high levels of proinflammatory chemokines, such as CXCR1 and CCR2 only in cells derived from wild-type mice, but not in AIM2-ko or NLRP3/AIM2-dko mice. The presence of these cells and their activity suggested AIM2 stimulation in this tissue by DNA,8 the source of which most likely were necrotic tubular cells. To this end, the authors used macrophage lineage specific LysM:cre mice that were transfected with a green fluorescent protein (gfp). Additional staining for DNA by SYTOX orange allowed for direct detection of DNA released from tubular cells to be taken up by LysM-gfp–positive cells with two-photon intravital microscopy. These experiments clearly demonstrate the uptake of necrotic cell released DNA by renal macrophages in living animals. However, the authors decided to add yet another line of evidence by treating THP1 cells (a macrophage cell line) with DNA generated from necrotic human tubular epithelial cells. Within 2 hours, the DNA released by the necrotic cell was taken up by the THP1 cells and IL-1β release was demonstrated to be highly increased in a caspase-sensitive manner. As expected, addition of DNase to the media destroyed the human tubular epithelial cell DNA and prevented the increased release of IL-1β.

Necrosis of renal tubular cells has recently been identified as a major driver of acute kidney injury in models of cisplatin-induced nephrotoxicity, folic acid–induced nephropathy, ischemia–reperfusion injury, and during kidney transplantation.1 As now demonstrated by Komada et al.,5 necrotic DNA is sensed, at least partially, by the AIM2 inflammasome to drive macrophage IL-1β release (Figure 1). These experiments support the model of necroinflammation (necrosis-driven potentiation of the initial damage by infiltrating immune cells).9,10 Two therapeutic options evolve from these findings. First, it should be possible to prevent the necrotic cell death per se. Second, if necrosis cannot be prevented, targeting inflammasomes provides an attractive

![Figure 1. AIM2-mediated sensing of DNA released from necrotic cells. Upon acute tubular necrosis, tubular cells release intracellular content. This necrotic debris contains damage-associated molecular patterns (DAMPs) such as DNA. Macrophages sense DNA released from necrotic cells through the AIM2 inflammasome and subsequently produce proinflammatory cytokines, such as IL-1β and IL-18. The amplification of the immunogenicity of a necrotic DAMP into a stronger proinflammatory signal is referred to as necroinflammation.](image-url)
Evaluation of Potential Living Kidney Donors in the APOL1 Era

Barry I. Freedman¹ and Bruce A. Julian²

¹Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina; and²Department of Medicine, Division of Nephrology; University of Alabama at Birmingham School of Medicine, Birmingham, Alabama

doi: https://doi.org/10.1681/ASN.2018020137

Published online ahead of print. Publication date available at www.jasn.org.

Correspondence: Prof. Barry I. Freedman, Wake Forest School of Medicine, Section on Nephrology, Medical Center Boulevard, Winston-Salem, NC 27157-1053. Email: bfreedma@wakehealth.edu

Copyright © 2018 by the American Society of Nephrology

Inheriting two apolipoprotein L1 gene (APOL1) renal risk variants accounts for the majority of the excess risk for nondiabetic ESRD in individuals with recent African ancestry.¹ APOL1 renal risk variants are common in blacks in the United States, with about 13% carrying two variants (defining the high-risk genotype), whereas 39% have one variant and 48% have no variant. In contrast, APOL1 renal risk variants are virtually absent in nonadmixed European, Asian, and Hispanic populations. Approximately 20% of those with the APOL1 high-risk genotype ultimately develop CKD, supporting the postulate that modifying factors are necessary to trigger development of nephropathy.²

The effect of having two APOL1 renal risk variants extends beyond native kidney disease. Kidney transplants from deceased black donors with the APOL1 high-risk genotype fail more quickly than allografts from donors with zero or one APOL1 renal risk variant.³ The outcomes of kidneys from deceased black donors with zero or one APOL1 renal risk variant approximate those of kidneys from white donors.³,⁴ Furthermore, serum creatinine concentrations are higher in recipients with functioning kidneys from donors with the APOL1 high-risk genotype, raising concerns that additional allografts will also fail over longer intervals.³,⁵ The poorer outcome of these allografts is independent of the ethnicity of the recipient, indicating that the effect of the genotype travels with the kidney.⁶ Nonetheless, such as is the case for native kidney disease, the association of the APOL1 high-risk genotype with a poor outcome is far from universal. Indeed, most allografts from deceased black donors with the APOL1 high-risk genotype function well for prolonged intervals, again suggesting that modifying factors initiate or accentuate renal damage.

More recently, the kidney transplant community has begun to examine a possible effect of APOL1 renal risk variants on outcomes in living donor transplantation. Living black kidney donors more often develop ESRD than donors from other racial groups, with frequencies about 3.5- to 5.3-fold higher than in age- and sex-matched whites⁷ (Figure 1). Patient reports have described the loss of kidneys from living black donors with the APOL1 high-risk genotype, a frequency similar to that described the loss of kidneys from living black donors with the APOL1 high-risk genotype several years after transplantation due to proteinuric disease, with subsequent development of ESRD in the donor.⁸ These reports raise the question: does the presence of the APOL1 high-risk genotype adversely affect postdonation renal function in black living kidney donors?

In this issue of the Journal of the American Society of Nephrology, Doshi et al.⁹ addressed that question by studying a cohort of 136 black living kidney donors with mean age of 37 years and mean follow-up of 12 years. Nineteen (14%) patients had the APOL1 high-risk genotype, a frequency similar to that in the general black population. They found that the mean eGFR before nephrectomy was significantly lower in APOL1 high-risk donors than in donors with zero or one APOL1 renal risk variant. This difference suggests that deterioration of renal clearance function started before donation, although without clinical manifestations that would preclude acceptance as a kidney donor. Nephrectomy decreased eGFR by 25–30 ml/min per 1.73 m² in both donor subgroups, but the decline in

See related article, “Macrophage Uptake of Necrotic Cell DNA Activates the AIM2 Inflammasome to Regulate a Proinflammatory Phenotype in CKD,” on pages 1165–1181.

References